Protein / target
Platelet-derived growth factor receptor alpha
Protein at a glance
Biological role
Transmembrane receptor protein tyrosine kinase
Strongest disease association
GIST-plus syndrome
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis.
View complete UniProt function annotationHide complete annotation
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor
Subcellular location
Domains and Gene Ontology detail (58)Hide
Domains & features
Gene Ontology
- Ccilium
- Ccytoplasm
- Cendoplasmic reticulum membrane
- Cexternal side of plasma membrane
- CGolgi apparatus
- Cmembrane
- Cmicrovillus
- Cnucleus
- Cplasma membrane
- Cprotein-containing complex
- Creceptor complex
- FATP binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·positive regulation of cell population proliferation
- ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…
- ·PIP3 activates AKT signaling
- ·PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
Cell migration
- ·Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC…
- ·cell chemotaxis
- ·cell migration
- ·positive regulation of cell migration
Growth-factor signalling
- ·platelet-derived growth factor binding
- ·vascular endothelial growth factor binding
- ·platelet-derived growth factor receptor signaling pathway
- ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…
Receptor tyrosine kinase signalling
- ·transmembrane receptor protein tyrosine kinase activity
- ·cell surface receptor protein tyrosine kinase signaling pathway
Oncogenic signalling
- ·Constitutive Signaling by Aberrant PI3K in Cancer
Haemostasis
- ·Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC…
- ·negative regulation of platelet activation
- ·platelet aggregation
- ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…
View underlying pathways (13)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
15 medicines meet Open Targets' target-level approved-medicine definition; the 5 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Platelet-derived growth factor receptor alpha antagonist
Indicated for Sarcoma, Neoplasms
Platelet-derived growth factor receptor alpha inhibitor
Indicated for Gastrointestinal Stromal Tumors, Neoplasms
Platelet-derived growth factor receptor alpha inhibitor
Indicated for Carcinoma, Renal Cell, Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, Neoplasms
Platelet-derived growth factor receptor inhibitor
Indicated for Colorectal Neoplasms, Neoplasms
Platelet-derived growth factor receptor inhibitor
Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene PDGFRA
Gene-level evidence surfaced through the gene PDGFRAthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
33 compounds recorded · 15 approved · 18 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Strong
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (13)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationLenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
- New publicationMachine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.
- New publicationGenomic profiling in GIST: Implications in clinical outcome and future challenges.
- New publicationNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
- Regulatory approval
Approval: Sunitinib Accord (EMA)
- Regulatory approval
Approval: Ayvakyt (EMA)
- New publicationPembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
- New publicationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
- Regulatory approval
Approval: Rydapt (EMA)
- New publicationRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Regulatory approval
Approval: Stivarga (EMA)
- Regulatory approval
Approval: Sutent (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Related literature
Papers indexed under “Receptor, Platelet-Derived Growth Factor alpha” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.